Characterization of Mycobacterium Abscessus Subtypes in Shanghai of China

Drug Sensitivity and Bacterial Epidemicity as well as Clinical Manifestations

Liulin Luo, PhD, Bing Li, PhD, Haiqing Chu, PhD, Dongdong Huang, MS, Zhemin Zhang, MS, Jingbo Zhang, MS, Tao Gui, MS, Liyun Xu, MS, Lan Zhao, PhD, Xiwen Sun, PhD, and Heping Xiao, PhD

Abstract: The aim of the study was to investigate the epidemic characteristics of Mycobacterium abscessus in Shanghai.

Fifty-five strains from 55 M. abscessus pulmonary disease patients were isolated. Drug sensitivity was measured by a broth microdilution method. Subtypes of M. abscessus were identified by DNA sequencing. Multilocus sequence typing (MLST), mining spanning tree (MST), and pulsed-field gel electrophoresis (PFGE) were used to analyze sequence types (ST) and clonal complexes (CC). Clinical manifestations were assessed by CT imaging.

We identified 4 A isolates, 11 M, and 2 B-subtypes. A and M were highly sensitive to tigecycline and amikacin (97.6–100%). The A-type easily developed drug resistance against clarithromycin. Both types were highly resistant to sulfonamides, moxifloxacin, doxycycline, imipenem, and tobramycin. MLST analysis identified 41 STs including 32 new STs. The MST algorithm distributed 55 isolates into 12 separate CC. The PFGE analysis exhibited 53 distinct restriction patterns and the M-type was closely clustered according to their ST and CC numbers. CT imaging showed that tree-in-bud and patch shadow were commonly observed in M-type, whereas pulmonary cavities were often found in A-type infection patients (P < 0.001).

Editor: Yong Wang.
Received: August 4, 2015; revised: November 22, 2015; accepted: November 27, 2015.

INTRODUCTION

Nontuberculous mycobacteria (NTM) have an extensively wide pathological spectrum including NTM pulmonary diseases, lymphadenopathy, and skin and soft tissue infections. Because of their ubiquitous distribution, NTM can cause nosocomial infections and epidemic outbreaks. In recent years, the incident of NTM infectious diseases has significantly increased due to the ascending NTM infection rate, especially among immunocompromised patients, and an increase in invasive surgical operations. The development of molecular diagnostic technology has shown that the diseases caused by NTM cannot be neglected in the clinic.

NTM is divided into 2 groups, namely rapidly growing mycobacteria (RGM) and slowly growing mycobacteria. RGM, for example, can cause an extensive pulmonary infection. In Japan and America, ~5% of pulmonary infections are caused by
RGM, and ~65% to 80% of RGM infections are due to Mycobacterium abscessus. An American group showed that M. abscessus was responsible for >80% of pulmonary infections caused by rapidly growing NTM. A Korean study demonstrated that M. abscessus ranked only second to Mycobacterium avium, accounting for 12% of 17,915 NTM strains clinically isolated. The Brazilian government reported the identification of M. abscessus infection in ~2,000 patients at surgical sites, and this agent once caused a state of emergency after an epidemic outbreak from 2004 to 2008. Besides pulmonary disease, M. abscessus can also cause lesions of lymph nodes, skin soft tissues and bone joints, and general pathological infections. The bacteria easily elicits outbreaks of infection in postsurgical wounds, and a disseminated infection in cystic fibrosis patients after transplantation. Currently, treatment of M. abscessus pulmonary disease relies on broad-spectrum antibiotics combined with others. However, an occurrence of drug resistance and natural resistance to antituberculosis drugs often makes the treatment ineffective. Although antibiotics such as amikacin, cefoxitin, or imipenem are known to be effective against M. abscessus, there is a high occurrence of drug resistance and also intolerable gastrointestinal toxicity. Thus, the prognosis of M. abscessus pulmonary disease is presently not promising.

According to the differences in DNA sequences of heat shock protein 65 (hsp65), RNA polymerase β (rpoB), and erythromycin ribosomal methylase 41, known as erm(41), and the differences of drug sensitivity, M. abscessus is divided into 3 subtypes: M. abscessus (A-type), M. massiliense (M-type), and M. bolletii (B-type). Some studies have shown differences between subtypes of M. abscessus in terms of their biological characteristics, antibiotic sensitivity, and clinical features (efficacy and prognosis are unpredictable), indicating a complex molecular identification, molecular typing, and drug sensitivity profile. Subtype analysis is a powerful technique for discovering and controlling an epidemic outbreak, and also for treating patients with M. abscessus infections. However, in the Shanghai district of China, molecular typing and analysis of the phylogenetic relationships of M. abscessus strains, as well as the corresponding clinical material analysis, have not been systematically carried out.

The aim of the present study was to investigate the epidemic characteristics of M. abscessus in the Shanghai district. We analyzed the antibiotic sensitivities of the bacteria subtypes, evaluated the evolution and epidemic dissemination of the strains with molecular typing, and identified the clinical features and characteristics of the subtypes, in order to provide reference evidence for the diagnosis and treatment of M. abscessus infection in the Shanghai district.

MATERIALS AND METHODS

Patient Material, Bacteria Culturing and Identification

Materials from 55 patients who suffered from M. abscessus pulmonary disease were retrospectively analyzed. Patients underwent the initial diagnosis and treatment at the Shanghai Pulmonary Hospital Affiliated to Tongji University from January 2013 to December 2014, and the diagnostic criteria were in accordance with the American Thoracic Association Guidelines. All patients were given a CT scan and spumut, lavage fluid, pleural effusion, and biopsy samples were collected to aid the initial diagnosis. Mycobacterium abscessus infection was confirmed by bacterial culture and strain identification, and all the specimens were preserved at -80°C for further investigations. The study was approved by the Ethical Committee of Tongji University and by the Shanghai Pulmonary Hospital. All the participants signed informed consent forms before being enrolled.

A total of 55 microbiological specimens were inoculated on the slope of acid Lowenstein–Jensen (L–J) medium after alkali treatment with 4% NaOH. Cultivated bacterial colonies were acid-fast stained with auramine O (1 mg/mL) and then examined microscopically to identify acid-fast bacteria colonies. To select further NTM, positive colonies were inoculated and cultured in L-J medium with P-nitrobenzoic acid (0.5 mg/mL) and 2-thiophenecarboxylic acid hydrazide (5 µg/mL) at 37°C for 1 to 2 weeks. Bacteria isolates that rapidly grew in this medium were selected for molecular typing analysis using PCR. To prepare DNA, bacteria were split with lysozyme (1 mg/mL) and digested with proteinase K (1 mg/mL) followed by phenol/chloroform extraction. First, the rpoB gene was amplified by PCR and the DNA sequences were determined. To confirm the M. abscessus complexes, 754 bp of the DNA segment was subjected to BLAST analysis. Second, the erm(41) gene was amplified and the DNA sequence was analyzed to identify M. massiliense, A (M. abscessus), and B (M. bolletii) subspecies. Finally the PRA-hsp65 gene was compared to an online reference (http://app.chuv.ch/prasite/index.html), when the A- and B-types were confirmed. Sequences and the length of primers are shown in Table 1. The methods were carried out in “accordance” with the approved guidelines.

Drug Sensitivity Assay

A broth micro-dilution method was used for the drug sensitivity assay. Bacteria were added to Middlebrook 7H9 medium containing glass beads (3 mm) for enrichment. Then an appropriate quantity of bacteria were suspended and diluted in a 3 mL saline solution to produce a turbidity of 0.5 McFarland (MFC). Each 50 µL suspension was inoculated in 11 mL of cation-adjusted Mueller-Hinton medium and then dispersed into 100 µL medium containing different concentrations of antibiotics in 96-well microtiters plates producing a final bacteria concentration of 10⁶ CFU/mL. After culturing for 72 h at 37°C, growth was assessed and drug sensitivity was calculated according to CLSI-M24-A2 criteria. The antibiotics tested were sulfonamides, moxifloxacin, cefoxitin, amikacin, doxycycline, tigecycline, clarithromycin, linezolid, imipenem, and tobramycin (TREK Diagnostic Systems, USA).

Phylogenetic Analysis of Strains by Multilocus Sequence Typing (MLST) and Mining Spanning Tree (MST)

The following 7 housekeeping genes were used for MLST sequencing analysis: arginosuccinate lyase (ars); adenyl cyclase (cya); glycerol kinase (gkp); 6-phosphogluconate dehydrogenase (gnd); UDP N-acetylmuramate-L-Ala ligase (murC); phosphate acetyltransferase (pta); phosphoribosylaminomimidazole carboxylase ATPase subunit (purH). The DNA sequence of primer pairs for each gene is shown in Table 1. The sequences were modified according to references in the MLST website (http://www.pasteur.fr/recherche/genopole/PF8/mlst/primerabscessus.html). Consensus sequences were established using the Bioedit software program ver. 7.1.3.0 and were compared and analyzed according to references in the MLST website (http://www.pasteur.fr/cgi-bin/genopole/PF8/mlstdbnet.pl?page =oneseq&file=Mabscessus_profiles.xml) website. Acquired information of allele combinations was submitted to the allele distribution inquiry website (http://www.pasteur.fr/cgi-bin/
TABLE 1. DNA Sequences of Primers Used for Multilocus Sequence Typing (MLST) and Subtyping

| Gene     | Primer      | Sequence (5'-3')              | Amplicon (bp) |
|----------|-------------|--------------------------------|---------------|
| 441hsp65 | PRA-hspF    | CTGAAACGGTTCCACATCG            | 441           |
|          | PRA-hspR    | AAGGCTTCTCGGTGGCGCA            |               |
| rpoB     | MycF        | TCCGATAGTGGCGTGGCA             | 940           |
| ermF     | MycR        | ACTTTGATGTCACACGTCC            |               |
| Erm (41) | ermR        | GACCGGGGCTTTTCCTGTGAT          | 673 or 397    |
| argH     | ARGHF       | GAGCAGGGCGGACAGGCTC            | 480           |
| argH     | ARGHISR1    | GTGCGGAGCAGATGATG              |               |
| cya      | ACFSR1      | GTGACAGGCCACGATG              | 510           |
| gnd      | GNDSR1      | GACGAGGCGACGATG               | 480           |
| murC     | MURCSF1     | CCGAGCAAAAGCGGCGCT            | 537           |
| pta      | PTASF1      | GATCGGGGCATGCCT               | 486           |
| PurH     | PURHSF1     | CAGGAGCCTACCCCTGAG            | 549           |
| PurH     | PURHSR2     | CAGGACCACAGCTGAT              |               |

argH = argininosuccinate lyase, cya = adenyl cyclase, Erm = erythromycin ribosomal methylase, gnd = 6-phosphogluconate dehydrogenase, hsp65 = heat shock protein 65, MLST = multilocus sequence typing, murC = UDP N-acetylmuramate-1-L-Ala ligase, pta = phosphate acetyltransferase, purH = phosphoribosylaminoimidazole carboxylase ATPase subunit, rpoB = RNA polymerase β.

Characterization of Mycobacterium Abscessus Subtypes in Shanghai

Analysis of Epidemic Strains by Pulsed-Field Gel Electrophoresis (PFGE)

All bacteria isolates were subjected to PFGE as previously described.613 Logarithmically growing bacteria were collected, washed with TE buffer (50 mM Tris:50 mM EDTA, pH 8.0 + 1% sarcosyl, and 1 mg/mL lysozyme). After adding lysozyme at a final concentration of 1 mg/mL, the suspension was incubated at 55°C for 2 h. Then the suspension was rapidly mixed with an equal volume of EC buffer containing 2% low-temperature-melting agarose and cast into plug molds. The plugs were allowed to solidify at 4°C, and placed in EC buffer containing lysozyme at a final concentration of 1 mg/mL, followed by shaking in an incubator overnight. Lysozyme containing EC buffer was replaced with cell lysis buffer (CLB) (50 mM Tris:50 mM EDTA, pH 8.0 + 1% Sarcosyl) and protease K was added at a final concentration of 1 mg/mL, and the plugs were incubated in a shaking bath at 55°C for 1 h. Then, the plugs were washed with TE buffer 3 times by shaking at 55°C for 15 min and were then placed in TE buffer containing 30 U Ase I restriction enzyme (New England Biolabs, UK) followed by incubation at 37°C for 3 h. After enzyme digestion, the plugs were loaded onto CHEF Mapper XA electrophoresis apparatus (Bio-Rad, USA) with 1% agarose and subjected to electrophoresis with a molecular standard marker. To obtain the PFGE gel images, the gels were stained with Gel red (1 mg/mL) (Biotium, USA) and placed in the imaging apparatus (Bio-Rad GelDoc XR+). The images were analyzed by BioNumericsver. 5.1 (Applied Maths, Sint-Martens-Latem, Belgium). The Dice’s coefficient correlation was used for fingerprint chromatography analysis with a tolerance index of 1%. Bacteria genotype grouping and classification as well as genotype similarity were attained utilizing the calculation of the unweighted pair group method with arithmetic mean (UPGMA).

CT Scanning

All CT images were obtained from the Radiology Department of Shanghai Pulmonary Hospital. CT scanning was performed within 3 months from the starting date of the acid-fast bacillus (AFB) smear test. Multislice spiral CT (Philips Brilliance 64) was used for routine CT scanning with a 1 mm thickness at 10 mm intervals. The scanning range was from the lung apex downward extending to the costophrenic angle under maximum inhalation. CT images were analyzed and...
interpreted by 4 CT imaging experts and 2 pulmonary disease experts who were blinded for the microbiological test results. The final interpretation was established by the consensus made by 3 experts. CT manifestations were evaluated according to the descriptions shown in Table 6.

**Statistical Analysis**

SPSS ver. 17.0 software (IBM SPSS Statistics for Windows, Version 17.0 Armonk, NY: IBM Corp) was used for statistical analysis. A chi-square test or Fisher’s exact test was used for the comparison of categorical variables. The independent nonpaired t test was used for the comparison of continuous variables. $P < 0.05$ was regarded as statistically significant.

**RESULTS**

**Subtype Identification of Bacteria Strains**

Fifty-five bacteria isolates were identified as *M. abscessus* complexes by MLST sequencing and BLAST comparative analysis of the rpoB gene. Among these, 11 strains were identified as M-type based on the result that their amplified fragment size of the erm(41) gene was 397 bp lacking 276 bp clarithromycin-resistance regions. The fragment size of the remaining strains was 673 bp, suggesting they were A- or B-types. To further identify A- and B-types, analysis of the restriction enzyme sites of the amplified fragments of the PRA-hsp65 gene (441 bp) was performed. Forty-two strains were identified as A-type, showing restriction patterns of BstE II 235 / 210 and HaeIII 145 / 70 / 60 / 55, whereas 2 strains were identified as B-type showing those of BstE II 235 / 210 and HaeIII 200 / 70 / 60 / 50.

**Comparison of Drug Sensitivity Between Subtypes**

A- and M-type strains were tested for drug sensitivity; however, the B-type was excluded because of its minute number of isolates. The results demonstrate that both strains were highly sensitive to intravenous antibiotics, such as tigecycline and amikacin, exhibiting sensitivity rates of 100% and 97.6%, respectively, against A-type and 100% and 100%, respectively, against the M-type. However, differences in the sensitivity between these 2 subtypes were not statistically significant ($P = 1.0$) (Table 2). Both subtypes showed moderate sensitivity to cefoxitin, clarithromycin, and linezolid, with the sensitivity ranging from 71.4% to 90.9%. Drug resistance against clarithromycin was easily induced in the A-type strain; in contrast, almost no induction was observed in the M-type. Both types showed a relatively high resistance with no statistically significant differences against sulfonamides, moxifloxacin, doxycycline, imipenem, or tobramycin.

**MLST Sequencing and Analysis of STs**

A comparative analysis utilizing references in the website www.pasteur.fr/mlst found neither base loss nor insertion in all the 7 housekeeping genes examined. Additionally, a new gene, ArgH34, was identified. Analysis of the 55 isolates demonstrated that the sequence types ST1 in the A-type and ST23 in the M-type were in the majority and that 32 new STs were identified. The data was submitted to the allele distribution inquiry website and new numbers ST179-ST211 were assigned. Bacteria isolates were subjected to the aggregation analysis by the NJ method together with reference strains (ATCC19977 for A-type, CIP18297 for M-type, and CIP108541 for B-type) and categorized into 3 groups; 42 strains in A-type with 33 STs, 2 in B-type with 2 STs, and 11 in M-type with 6 STs (Figure 1). The result was consistent with the sequencing analysis of the rpoB, erm(41), and PRA-hsp65 genes.

**Phylogenetic Relationship Analysis**

The analysis of the phylogenetic relationship between *M. abscessus* isolates was carried out using the MST method and utilizing the MLST sequencing results. Known strains containing 178 STs, published on the website www.pasteur.fr/mlst, were used as a reference. The 55 isolated were distributed to 12 CC out of 18 (we downloaded the data that was published in the Pasteur website and then used Bionumber software for re-analysis) that consisted of altogether 178 STs. A-type strains were assigned to 8 CC (CC4-CC11), M-type to 3 CC (CC1-CC3), and B-type to 1 CC (CC12) (Table 3). The maximum clonal complex in the A-type was CC5 consisting of 19 STs. Five A-type strains with 4 different STs (ST120, ST208, ST182, and ST63) were in CC5 and ST63 appeared to be the ancestor of CC5. Another 5 A-type strains with ST1 were assigned to CC11, to which the reference strain *M. abscessus* ATCC19977 was

### TABLE 2. Analysis of Antibiotic Sensitivity of *M. abscessus* (A-) and *M. massiliense* (M-) Type Strains

| Antimicrobials | MIC (µg/mL) in Broth Dilution | Number of Resistant Isolates |
|---------------|-------------------------------|-------------------------------|
|               | Susceptible | Intermediate | Resistant | A-Type | M-Type | $P$ |
| SXT (sulfonamides) | ≤ 2 | NA | ≥ 4 | 26/42 (61.9) | 11/11 (100) | 0.4551 |
| MXF (moxifloxacin) | ≤ 1 | 2 | ≥ 4 | 40/42 (95.2) | 11/11 (100) | 1.0 |
| FOX (cefoxitin) | ≤ 16 | 32–64 | ≥ 128 | 12/42 (28.6) | 3/11 (27.3) | 1.0 |
| AMI (aminoglycoside) | ≤ 16 | 32 | ≥ 64 | 1/42 (2.4%) | 0/11 (0) | 1.0 |
| DOX (doxycycline) | ≤ 1 | 2–4 | ≥ 8 | 41/42 (97.6) | 11/11 (100) | 1.0 |
| TGC (tigecycline) | ≤ 1 | NA | NA | 0/42 (0) | 0/11 (0) | 1.0 |
| CLA (clarithromycin before induction) | ≤ 2 | 4 | ≥ 8 | 11/42 (26.2) | 4/11 (36.4) | 0.7264 |
| CLA (clarithromycin after induction) | ≤ 2 | 4 | ≥ 8 | 31/42 (73.8) | 5/11 (45.5) | 0.5752 |
| LZD (linezolid) | ≤ 8 | 16 | ≥ 32 | 10/42 (23.8) | 1/11 (9.1) | 0.6735 |
| IMI (imipenem) | ≤ 4 | 8–16 | ≥ 32 | 41/42 (97.6) | 11/11 (100) | 1.0 |
| TOB (tobramycin) | ≤ 2 | 4 | ≥ 8 | 33/42 (78.6) | 11/11 (100) | 0.6352 |

MIC = minimum inhibitory concentration.
FIGURE 1. Distribution of sequence types (STs) in 55 isolates by multilocus sequence typing (MLST). MLST = multilocus sequence typing, ST = sequence types.
assigned as well. Other A-type strains were assigned to CC6, CC7, and CC8, which were composed of newly identified STs (Table 3). The maximum clonal complex for the M-type strain was CC2 that included 6 strains with 2 different STs and among the 5 strains with ST23 appeared to be the ancestor of CC2. However, the reference strain M. massiliense (CIP108297) was not assigned to CC2, rather to other CC in which no strains isolated in our study were placed. Finally, only 1 of 2 B-type strains with ST204 was assigned to CC12.

The NJ method was used to analyze MLST sequencing results with bootstrap confidence interval set at 2000. The maximum likelihood method was used to calculate the phylogenetic relationship, and the reference strains used were ATCC19977, CIP18297, and CIP108541. CC was created by clustering STs according to MLST sequencing results. Each CC was composed of 2 or more STs and each ST contained 6 of the 7 housekeeping genes. The phylogenetic relationship was analyzed by the MST method.

**Phylogenetic Analysis of STs and CC by PFGE**

PFGE analysis of 55 isolates showed 53 distinct restriction patterns, with identical patterns being observed between isolates No. 183 and No. 206, and isolates between No. 130 and No. 76 (Figure 2). Clustering strains according to their PFGE patterns showed that 11 M-type strains were clustered as a big complex and 2 B-type strains were placed side by side among A-type strains. Most of the A-type strains were also clustered; however, isolate No. 177 was clustered with the M-type strains (Figure 3). The PFGE pattern clustering also demonstrated that almost all strains with the same ST numbers clustered together, with the exception of 2 strains with ST47 and ST61. With respect to CC, all M-type strains clustered according to their CC classification, whereas A-type strains assigned as well. Other A-type strains were assigned to CC6, CC7, and CC8, which were composed of newly identified STs (Table 3). The maximum clonal complex for the M-type strain was CC2 that included 6 strains with 2 different STs and among the 5 strains with ST23 appeared to be the ancestor of CC2. However, the reference strain M. massiliense (CIP108297) was not assigned to CC2, rather to other CC in which no strains isolated in our study were placed. Finally, only 1 of 2 B-type strains with ST204 was assigned to CC12.

The NJ method was used to analyze MLST sequencing results with bootstrap confidence interval set at 2000. The maximum likelihood method was used to calculate the phylogenetic relationship, and the reference strains used were ATCC19977, CIP18297, and CIP108541. CC was created by clustering STs according to MLST sequencing results. Each CC was composed of 2 or more STs and each ST contained 6 of the 7 housekeeping genes. The phylogenetic relationship was analyzed by the MST method.

**Phylogenetic Analysis of STs and CC by PFGE**

PFGE analysis of 55 isolates showed 53 distinct restriction patterns, with identical patterns being observed between isolates No. 183 and No. 206, and isolates between No. 130 and No. 76 (Figure 2). Clustering strains according to their PFGE patterns showed that 11 M-type strains were clustered as a big complex and 2 B-type strains were placed side by side among A-type strains. Most of the A-type strains were also clustered; however, isolate No. 177 was clustered with the M-type strains (Figure 3). The PFGE pattern clustering also demonstrated that almost all strains with the same ST numbers clustered together, with the exception of 2 strains with ST47 and ST61. With respect to CC, all M-type strains clustered according to their CC classification, whereas A-type strains assigned as well. Other A-type strains were assigned to CC6, CC7, and CC8, which were composed of newly identified STs (Table 3). The maximum clonal complex for the M-type strain was CC2 that included 6 strains with 2 different STs and among the 5 strains with ST23 appeared to be the ancestor of CC2. However, the reference strain M. massiliense (CIP108297) was not assigned to CC2, rather to other CC in which no strains isolated in our study were placed. Finally, only 1 of 2 B-type strains with ST204 was assigned to CC12.

The NJ method was used to analyze MLST sequencing results with bootstrap confidence interval set at 2000. The maximum likelihood method was used to calculate the phylogenetic relationship, and the reference strains used were ATCC19977, CIP18297, and CIP108541. CC was created by clustering STs according to MLST sequencing results. Each CC was composed of 2 or more STs and each ST contained 6 of the 7 housekeeping genes. The phylogenetic relationship was analyzed by the MST method.

**Clinical Manifestations and Analysis of CT Results**

Because of the limited numbers of STs and CC in isolated strains in this study, it was difficult to analyze the relationships between molecular typing, drug sensitivity, and clinical manifestations. Therefore, clinical characteristics and CT images of 55 patients were analyzed according to the subtypes of M. abscessus. Among 42 patients infected with the A-type strain, 22 were men and 20 were women, with a median age of 57 years. Among 11 patients infected with the M-type strain, 5 were men and 6 were women, and the median age was 52 years. No statistically significant differences were found in the distribution of gender, age, smoking history, underlying diseases, or clinical symptoms in these 2 groups. The patients’ clinical characteristics are summarized in Table 4.

CT manifestations of patients with A- and M-type bacterial infection are summarized in Table 5. Common CT manifestations observed in A-type patients were bronchiectasis (39/42), cavity of various types (29/42, 17/42, 25/42 and 9/42), and patch shadow (13/42), whereas the CT manifestations in M-type patients were bronchiectasis (8/11), patch shadow (4/11), and tree-in-bud (5/11). Manifestations such as thin-walled small cavity (d < 3 cm) (P = 0.002), thin-walled big cavity (d ≥ 3 cm) (P = 0.005), and thick-walled small cavity (d < 3 cm) (P = 0.001) (Figure 4A–C) were more common in A-type patients (Table 6). CT examination further showed that in patients with thin-walled small cavities (d < 3 cm) and patients with thick-walled small cavities, the range of the lesion involving the lung lobe was more extensive. CT manifestations such as tree-in-bud and patch shadow (Figure 4D and E) were more common in M-type patients (P < 0.001, P = 0.012). The incidence rate of overall cavities in A-type patients was significantly higher than that in M-type patients (P < 0.001) (Table 6).

Multislice spiral CT scanning was performed with 5 mm thick images at 5 mm intervals: A: thin-walled small cavity (d < 3 cm); B: thin-walled big cavity (d ≥ 3 cm); C: thick-walled small cavity (d < 3 cm); D: tree-in-bud; E: patch shadow.

---

**Table 3. Grouping of M. massiliense (M-), M. abscessus (A-), and M. bolletii (B-) Type Strains According to Clonal Complexes (CC) and Sequence Types (STs)**

| Type | NTM Strain (N) | CC Number | ST Number |
|------|---------------|-----------|-----------|
| M    | 2             | 1         | 210,34    |
|      | 6             | 2         | 23,48     |
|      | 2             | 3         | 117       |
|      | 1             | X         | 2         |
|      | 1             | 4         | 49        |
|      | 5             | 5         | 120,208,63,182 |
|      | 4             | 6         | 186,207,184 |
|      | 5             | 7         | 193,197,183,187,196 |
| A    | 3             | 8         | 181,189,195 |
|      | 3             | 9         | 47,211,200 |
|      | 1             | 10        | 22        |
|      | 5             | 11        | 1         |
|      | 14            | X         | 194,180,192,209,202,61,154,179,205,188,185,206 |
| B    | 1             | 12        | 204       |
|      | 1             | X         | 203       |

CC = clonal complexes, NTM = nontuberculous mycobacteria, STs = sequence types.
DISCUSSION

Our study showed that the A-subtype of *M. abscessus* is probably a major epidemic NTM in the Shanghai District of China, considering the high infection rate (76.4%, 42 of 55 patients) found in the present study. The result was consistent with findings in Beijing, Guangzhou, and other cities in China and in Europe as well; however, Korean research has shown that 46.8% (22 of 47 patients) had a slightly lower infection rate of the A-type.9 The drug sensitivity test showed that both the A-type and M-type were highly sensitive to tigecycline (A-type 100% and M-type 100%) and amikacin (A-type 97.6% and M-type 100%), in agreement with the results reported by Jeon et al (2014).9 The later authors tested the same 10 antibiotics except tigecycline and found that *M. abscessus* subtypes were highly sensitive to amikacin (A-type 96.2% and M-type 90.9%). Lyu et al (2014)20 also reported that amikacin was effective against both the A-type and M-type, and that clarithromycin had superior efficacy to amikacin. In our study, cefoxitin, clarithromycin, and linezolid showed some effectiveness against these 2 subtypes; however, the drug resistance to clarithromycin was easily induced in the A-type but not in the B-type (Table 2). *Mycobacterium abscessus* was highly resistant to moxifloxacin, doxycycline, imipenem, and tobramycin. Although the M-type is reported to be more resistant to imipenem than the A-type,17 we found that both subtypes were similarly highly resistant to imipenem (100% and 97.6%). Therefore, we recommend tigecycline and amikacin as the preferred treatment for *M. abscessus* pulmonary diseases in the clinic. Clarithromycin appeared to be more suitable to treat the M-type rather than the A-type, because of its lower rate of induced drug resistance.
We performed molecular typing of 55 bacteria strains isolated from patients and analyzing them with PFGE, MLST, and MST. A total of 32 new STs (ST179-ST211) were identified by MLST sequencing. Among all the detected STs, ST1 in A-type and ST23 in M-type were the major sequence types, strongly suggesting that they are predominantly responsible for epidemic transmission in the Shanghai District. This result agrees well with findings in other countries and regions in Europe, America, and Asia, substantiating the speculation that ST1 and ST23 are probably global epidemic types. The MST method was used to analyze further the phylogenetic relationships of the 55 isolates together with the reference strains with 178 STs. STs identified in our isolates were distributed in 12 different CC, and 5 of the A-type strains with ST1 were allocated in CC11, 5 with 4 different STs in CC5, and ST63 was speculated to be the ancestor of CC5, which is consistent with the European study, which reported 11 STs newly identified in A-type strains, and among those ST186, ST196,

### TABLE 4. Clinical Characteristics of Patients With *M. abscessus*-LD and *M. massiliense*-LD

|                      | *M. abscessus* (n = 42) | *M. massiliense* (n = 11) | P  |
|----------------------|-------------------------|---------------------------|----|
| Age                  | 57                      | 52                        | 0.585 |
| Male                 | 22                      | 5                         | 0.682 |
| BMI kg/m²            | 20.3                    | 20.6                      | 0.701 |
| Ever smoker          | 18                      | 3                         | 0.494 |
| Underlying disease   |                         |                           |    |
| Previous tuberculosis| 20                      | 4                         | 0.735 |
| Diabetes mellitus    | 5                       | 2                         | 0.626 |
| Malignancy           | 1                       | 0                         | 0.398 |
| Autoimmune disease   | 1                       | 0                         | 0.398 |
| COPD                 | 5                       | 1                         | 1.0  |
| Symptoms             |                         |                           |    |
| Cough                | 35                      | 7                         | 0.210 |
| Sputum               | 35                      | 7                         | 0.210 |
| Hemoptysis           | 12                      | 2                         | 0.706 |

BMI = body mass index, LD = lung disease.

FIGURE 3. Phylogenetic distribution of clonal complexes (CC) in 55 isolates by mining spanning tree (MST). CC = clonal complexes, MLST = multilocus sequence typing.
| CT Manifestations            | Laterality | M. abscessus (A-type) | Laterality | M. massiliense (M-type) |
|-----------------------------|------------|-----------------------|------------|-------------------------|
|                             | Bi Uni RUL RML RLL LUL LL LLL SUM | Bi Uni RUL RML RLL LUL LL LLL SUM |            |                         |
| Tree-in-bud pattern         | 0 1 1 0 0 0 0 0 0 1 | 0 3 2 2 1 2 1 2 5 0 14 |            |                         |
| Nodules (d ≥ 1cm)           | 0 2 0 0 0 0 1 1 2 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Bronchiectasis              | 26 13 8 30 7 5 23 12 85 5 | 5 1 1 0 0 0 1 0 1 3 |            |                         |
| Thin-walled cavity (d < 3cm)| 10 19 10 9 10 9 2 7 47 1 | 1 1 1 0 0 0 1 0 1 3 |            |                         |
| Thin-walled cavity (d ≥ 3cm)| 4 13 9 0 2 5 2 4 22 1 | 0 1 0 0 0 0 1 0 0 2 |            |                         |
| Thick-walled cavity (d < 3cm)| 5 20 10 4 3 11 4 6 38 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Thick-walled cavity (d ≥ 3cm)| 2 7 6 1 0 1 1 2 11 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Consolidation               | 0 1 1 0 0 0 0 0 0 1 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Patches                     | 2 11 7 0 4 2 0 2 15 4 | 4 4 2 2 4 4 0 5 17 4 |            |                         |
| Nodules (d < 1 cm)          | 0 7 6 0 0 0 0 0 1 7 | 1 2 1 0 1 1 0 1 1 4 |            |                         |
| Atelectasis                 | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Ground-glass opacity        | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Reticular opacities         | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Volume reduction            | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Mediastinal lymphadenopathy | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Hilair lymphadenopathy      | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Calcified lymph nodes       | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Cystic changes              | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Pleural effusion            | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Interstitial fibrosis       | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Pneumothorax                | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |
| Pleural thickening          | 0 0 0 0 0 0 0 0 0 0 | 0 0 0 0 0 0 0 0 0 0 |            |                         |

Bi = bilateral, LL = left lingual, LLL = left lower lobe, LUL = left upper lobe, RML = right middle lobe, RUL = right upper lobe, SUM = summation, Uni = unilateral.

**FIGURE 4.** CT images of patients infected with *M. abscessus* (A-type) and *M. massiliense* (M-type). (A) Thin-walled small cavity in A-type patients’ CT scan, (B) thin-walled big cavity in A-type patients’ CT scan, (C) thick-walled small cavity in A-type patients’ CT scan, (D) tree-in-bud pattern in M-type patients’ CT scan, (E) patchy in M-type patients’ CT scan.
and T189 appeared to be the ancestors of these CC, respectively. This result could enrich the database of the A-type strain and also suggests that some of the newly created CC might be specific to and have originated in the Shanghai District of China; however, further studies are required to back up this supposition. In M-type strains, ST23 was most abundant followed by ST117 and ST34. All of them finely aggregated into clusters with STs identified in Brazil, Ireland, France, and other European countries.23

To further assess the epidemic dissemination of these strains, we carried out PFGE typing analysis. The 55 isolates showed 53 distinct restriction patterns. The PFGE pattern showed that M-type strains clustered together according to their ST and CC numbers, consistent with the MLST analysis (Figure 2). Since Bryant et al (2013)22 reported that M-type strains with small sequence variations could indicate epidemiological nosocomial transmission among patients, the M-type might be largely responsible for such transmission in the Shanghai district as well. Although the A-type was the most common bacteria in our isolates, they, except one with ST1, dispersed into different clusters in the PFGE analysis. The results suggested that M-type strains also play an important role in epidemic transmission in this region; therefore, an expanded study with larger numbers of M-type strains is currently in progress and we plan to perform next-generation sequencing to receive more detailed information, such as SNPs and more MLST genes for comparison, which might be helpful for us to identify transmission routes.

Clinical treatment is a complicated and a time-consuming process. NTM pulmonary diseases are extremely difficult to treat, as shown by Japanese research in which the antibiotic treatment of patients infected with A-subtypes of \textit{M. abscessus} required a longer mean duration of treatment (3–178 months) compared to M-subtypes (1–122 months). The Japanese research also reported that compared to patients with M-type, patients with A-type showed less improvement after antibiotic treatment, as evidenced by CT imaging. We found no significant difference between patients with the A-type and B-type in their clinical baseline characteristics, such as age and gender (Table 4). However, CT imaging analysis showed that in patients infected with the A-type, the rate of occurrence of pulmonary cavities was significantly higher than in patients with M-type. Furthermore, these cavities were characterized mainly by thin-walled small cavities and thick-walled small cavities, with more extensive lung lobe involvement (Tables 5 and 6). Harada et al reported that their antibiotic sensitivity tests, clinical treatments of patients, and follow-up observations revealed that drug treatments are more effective in patients with M-type than A-type infections, although bronchiectasis was more common in A-type (\( P = 0.014 \)).17 This finding was supported by Koh et al18 who reported that the A-type strain was more prone to drug resistance resulting in a poor response to antibiotics such as clarithromycin. Our finding of frequent and severe pulmonary cavities in patients with the A-type strain is in good agreement with the later report. Formation of cavities makes infection more refractory, reducing the therapeutic effect, delaying healing and also increasing the risk of the induction of drug resistance. In addition, pulmonary imaging of patients with A-type infections showed small airway inflammation and inflammatory exudation. The extent of pulmonary destruction in patients with the M-type was less severe and the prognosis of these patients was superior to that of A-type patients. However, it is worth noting that both A- and M-type strains, without statistical differences, cause a wide range of bronchiectasis with different degrees of nodule shadows.

In conclusion, we found that ST1 in the A-subtype and ST23 in the M-subtype of \textit{M. abscessus} isolated in the Shanghai district of China were the main sequence types of epidemic strains. The M-type strain was more prone to epidemic

### Table 6. Comparative Chest CT Findings of Patients With \textit{M. abscessus} (A-type) and \textit{M. massiliense} (M-Type)

| CT Findings                  | Number of Patients | Number of Involved Lobes |
|------------------------------|--------------------|--------------------------|
| A-Type\(^1\) (n = 42)        | M-Type\(^2\) (n = 11) | \( P \)                  |
| Tree-in-bud pattern          | 1                  | 5                        | < 0.001                  |
| Nodules (\( d \geq 1\)cm)    | 2                  | 2                        | 0.141                    |
| Bronchiectasis               | 39                 | 8                        | 0.875                    |
| Thin-walled cavity (\( d < 3 \)cm) | 29                 | 2                        | 0.002                    |
| Thick-walled cavity (\( d \geq 3 \)cm) | 17                 | 1                        | 0.05                     |
| Thick-walled cavity (\( d < 3 \)cm) | 25                 | 0                        | < 0.001                  |
| Thick-walled cavity (\( d \geq 3 \)cm) | 9                  | 0                        | 0.092                    |
| Consolidation                | 1                  | 0                        | 0.605                    |
| Patches                      | 13                 | 8                        | 0.012                    |
| Nodules (\( d < 1 \)cm)      | 7                  | 3                        | 0.424                    |
| Atelectasis                  | 0                  | 0                        | 0                        |
| Ground-glass opacity         | 0                  | 0                        | 0                        |
| Reticular opacities          | 0                  | 0                        | 0                        |
| Volume reduction             | 0                  | 0                        | 0                        |
| Mediastinal lymphadenopathy  | 0                  | 0                        | 0                        |
| Hilar lymphadenopathy        | 0                  | 0                        | 0                        |
| Calcified lymph nodes        | 0                  | 0                        | 0                        |
| Cystic changes               | 0                  | 0                        | 0                        |
| Pleural effusion             | 0                  | 0                        | 0                        |
| Interstitial fibrosis        | 0                  | 0                        | 0                        |
| Pneumothorax                 | 0                  | 0                        | 0                        |
| Pleural thickening           | 0                  | 0                        | 0                        |

\(^{1}\) Number of patients who underwent CT imaging. \(^{2}\) Number of patients who underwent CT imaging.
appropriate the use of a combination of linezolid and cefoxitin
treatment of tigecycline and amikacin is recommended and if
the frequent occurrence of drug resistance. A combination
with clarithromycin needs to be carefully monitored because of
nosocomial transmission. Clinical treatment of A-type patients
with clarithromycin needs to be carefully monitored because of
the frequent occurrence of drug resistance. A combination
with clarithromycin needs to be carefully monitored because of

REFERENCES

1. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of
pathogenic nonpigmented or late-pigmenting rapidly growing myco-
bacteria. Clin Microbiol Rev. 2002;15:716–746.

2. Tiwari TS, Ray B, Jost KC Jr et al. Forty years of disinfectant
failure: outbreak of postinjection Mycobacterium abscessus infection
caused by contamination of benzalkonium chloride. Clin Infect Dis.
2003;36:954–962.

3. Villanueva A, Calderon RV, Vargas BA, et al. Report on an out-
break of postinjection Mycobacterium abscessus, including manage-
ment with surgery and clarithromycin therapy and comparison of strains by random amplified
polymorphic DNA polymerase chain reaction. Clin Infect Dis.
1997;24:1147–1153.

4. Wallace RJ Jr, Brown BA, Griffith DE. Nosocomial outbreaks/
pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev
Microbiol. 1998;52:453–490.

5. Tortoli E. Clinical manifestations of nontuberculous mycobacteria
infections. Clin Microbiol Infect. 2009;15:906–910.

6. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontubercu-
los mycobacterial diseases. Am J Respir Crit Care Med.
2007;175:367–416.

7. Benwill JL, Wallace RJ Jr. Mycobacterium abscessus: challenges in
diagnosis and treatment. Curr Opin Infect Dis. 2014;27:506–510.

8. Chadha R, Grover M, Sharma A, et al. An outbreak of post-surgical
wound infections due to Mycobacterium abscessus. Pediatr Surg Int.
1998;13:406–410.

9. Jeon SM, Lim NR, Kwon SJ, et al. Analysis of species and intra-
species associations between the Mycobacterium abscessus complex strains using pulsed-field gel electrophoresis (PFGE) and multi-
locus sequence typing (MLST). J Microbiol Methods. 2014;104:
19–25.

10. O’Driscoll C, Konjek J, Heym B, et al. Molecular epidemiology of
Mycobacterium abscessus complex isolates in Ireland. J Cyst Fibros.
2015. DOI: 10.1016/j.jcf.2015.05.007.

11. Society, AT. Diagnosis and treatment of disease caused by
nontuberculous mycobacteria. This official statement of the Amer-
ican Thoracic Society was approved by the Board of Directors,
March 1997. Medical Section of the American Lung Association.
Am J Respir Crit Care Med. 1997;156:S1–25.

12. ANVIS.A. Relatório descrito de investigação de casos de infecçõespseudomicobacterianas tuberculose de crescimentorápido
(MCR) no Brasilinoperíodo de 1998 a 2009. Agência Nacional de Vigilância Sanitária, Brasília, Brazil. 2012.http://www.anvisa.gov.br/
hotsite/hotsite_micobacteria/relatorio_descrito_mcr_16_02_11.pdf.

13. Adekambi T, Colson P, Drancourt M. rpoB-based identification of
nonpigmented and late-pigmenting rapidly growing mycobacteria.
J Clin Microbiol. 2003;41:5699–5708.

14. Leao SC, Tortoli E, Euzéby JP, et al. Proposal that Mycobacterium
massiliense and Mycobacterium bolletii be united and reclassified as
Mycobacterium abscessus subsp. bolletii comb. nov., designation of
Mycobacterium abscessus subsp. abscessus subsp. nov. and emended
description of Mycobacterium abscessus. Int J Syst Evol Microbiol.
2011;61:2311–2313.

15. Telenti A, Marchesi F, Balz M, et al. Rapid identification of
mycobacteria to the species level by polymerase chain reaction and
restriction enzyme analysis. J Clin Microbiol. 1993;31:175–178.

16. Diagnosis and treatment of disease caused by nontuberculous mycobac-
teria. This official statement of the American Thoracic Society was
approved by the Board of Directors, March 1997. Medical Section of
the American Lung Association. Am J Respir Crit Care Med. 1997;156:
S1–S25http://www.atsjournals.org/doi/abs/10.1164/ajrccm.156.2.
atstatement?url_ver¼Z39.88-2003&rfr_id¼or%3And%3Acrossref.org
&fr_dat=cr_pub%3Dpubmed%26rfr_pub%3DAWJX4.

17. Harada T, Akiyama Y, Kurashima A, et al. Clinical and micro-
biological differences between Mycobacterium abscessus and Myco-
bacterium massiliense lung diseases. J Clin Microbiol.
2012;50:3556–3561.

18. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentia-
tion of Mycobacterium massiliense from Mycobacterium abscessus.
Am J Respir Crit Care Med. 2011;183:405–410.

19. Clinical and Laboratory Standards Institute. Susceptibility testing of
mycobacteria, nocardia, and other aerobic actinomycetes; approved
Standard M24-A2. Wayne, PA: CLSI; 2011.

20. Lyu J, Kim BJ, Kim BJ, et al. A shorter treatment duration may be
sufficient for patients with Mycobacterium massiliense lung disease
than with Mycobacterium abscessus lung disease. Respir Med.
2014;108:1706–1712.

21. Choo SW, Woo WY, Ngeow YF, et al. Genomic reconnaissance of
clinical isolates of emerging human pathogen Mycobacterium
abscessus reveals high evolutionary potential. Sci Rep. 2014;4:4061.

22. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome
sequencing to identify transmission of Mycobacterium abscessus
between patients with cystic fibrosis: a retrospective cohort study.
Lancet. 2013;381:1551–1560.

23. Davidson RM, Hasan NA, de Moura VC, et al. Phylogenomics of
Brazilian epidemic isolates of Mycobacterium abscessus subsp.
bolletii reveals relationships of global outbreak strains. Infect Genet
Evol. 2013;20:292–297.